T1	p 173 238	patients with chronic heart failure after myocardial infarction .
T2	p 373 409	patients with heart failure ( HF ) .
T3	p 575 637	patients with class II to IV HF and ejection fraction < 35 % .
T4	p 1481 1579	HF patients with chronic postinfarction cardiomyopathy , transcatheter administration of myoblasts
T5	p 1852 1895	patients with postinfarction cardiomyopathy
T6	i 127 148	myoblast implantation
T7	i 152 169	catheter delivery
T8	i 312 356	transcatheter intramyocardial administration
T9	i 360 369	myoblasts
T10	i 418 424	MARVEL
T11	i 441 459	placebo-controlled
T12	i 469 554	image-guided , catheter-based intramyocardial injection of placebo or myoblasts ( 400
T13	i 994 1001	placebo
T14	i 1100 1110	amiodarone
T15	i 1164 1171	placebo
T16	i 1354 1361	placebo
T17	i 1570 1579	myoblasts
T18	i 1592 1595	400
T19	i 1599 1602	800
T20	i 1718 1726	myoblast
T21	i 1822 1830	myoblast
T22	i 1866 1895	postinfarction cardiomyopathy
T23	o 81 114	safety and cardiovascular effects
T24	o 662 792	frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy ) .
T25	o 947 964	numbers of events
T26	o 1053 1096	deaths . Ventricular tachycardia responsive
T27	o 1245 1264	functional capacity
T28	o 1314 1318	walk
T29	o 1432 1448	Minnesota Living
T30	o 1454 1463	HF scores